Pharmaids Pharmaceuticals Ltd (PHARMAID) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Pharmaids Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Pursuant to the Regulation 30(3) & 30(4) read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015, we hereby inform that the ....
Others (Uncategorized) · 16 Sept 2026, 11:21 pm
Pharmaids Pharmaceuticals Files ₹2.63 Crore Cheque Dishonour Complaints Against Anugraha Chemicals Pharmaids Pharmaceuticals filed two complaints on 15th Sep'26 before the 34th ACJM, Bengaluru, against Anugraha Chemicals and its partners under Section 138 of the NI Act and Section 223 of BNSS. The action follows the dishonour of two cheques totaling ₹2.63 crore (₹52.50 lakh and ₹2.10 crore), issued to discharge outstanding dues from the company's disinvestment exit from the partnership. Both cheques were dishonoured on 23rd Jul'26 with the remark "Payment Stopped by the Drawer." The litigation carries no financial liability for Pharmaids.
Voting Results along with the Scrutinizer''s Report of the 37th AGM of the Company held on 11th September 2026 through VC/ OAVM.
Annual General Meeting · 15 Sept 2026, 9:15 pm
Outcome of the 37th Annual General Meeting of the Company held on September 11, 2026 i.e., today at 12 noon through VC/OAVM.
Annual General Meeting · 11 Sept 2026, 9:23 pm
Annual Report
Others (Uncategorized) · 18 Aug 2026, 10:50 pm
Notice of 37th AGM and Annual Report
Annual General Meeting · 18 Aug 2026, 10:37 pm
Submission of unaudited financial results
Financial Result · 13 Aug 2026, 1:08 am
Pharmaids Pharmaceuticals Reports Q1 FY27 Results, Turning Profitable Pharmaids Pharmaceuticals reported its financial results for the quarter ended 30th Jun'26. On a consolidated basis, the company posted a net profit of Rs. 187.15 lacs, a significant turnaround from a loss of Rs. 531.53 lacs YoY. Revenue from operations declined 38.1% YoY to Rs. 412.14 lacs. An exceptional item of Rs. 420.00 lacs contributed to the profit before tax of Rs. 241.45 lacs. Consolidated EPS stood at Rs. 0.63, compared to Rs. (1.41) in the prior-year quarter.
Outcome of the Board meeting held today i.e. August 12, 2026
Outcome · 13 Aug 2026, 1:02 am
Pharmaids Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 412 (-38.2% YoY | -42.6% QoQ) ■ EBITDA: -74.4 (+86.2% YoY | -119.6% QoQ) ■ EBITDA Margin (%): -18.1 (+6312 bps YoY | -1334 bps QoQ) ■ PAT: 221 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 0.63 (Loss to Profit YoY | Loss to Profit QoQ)
Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 12 Aug 2026, 5:30 am
Pharmaids Pharmaceuticals Board Meeting on Aug 12, '26 for Q1FY27 Results Pharmaids Pharmaceuticals has scheduled a Board of Directors meeting on 12 Aug'26. The agenda includes the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ended 30 Jun'26. In line with this, the trading window for company securities has been closed since 01 Jul'26 and will reopen 48 hours after the financial results are declared. This meeting is a key event for the upcoming earnings announcement for Q1FY27.
Appointment of M/s. V Mahendra & Associates, as the Internal Auditors of the Company for carrying out the Internal Audit for the financial year 2026-27.
Change in Management · 01 Jul 2026, 12:46 am
Pharmaids Pharma Appoints V Mahendra & Associates as Internal Auditor for FY27 Pharmaids Pharmaceuticals' Board of Directors, on the recommendation of the Audit Committee, has appointed M/s. V Mahendra & Associates (FRN: 025356S) as its Internal Auditor. The appointment, effective 30 Jun'26, is for the financial year 2026-27. V Mahendra & Associates is a Chartered Accountant firm with over 23 years of professional experience in statutory compliance, internal controls, and financial reporting systems. This is a standard corporate governance disclosure under Regulation 30 of SEBI Listing Regulations.
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you of the change in Senior Management Personnel ....
Change in Management · 25 Jun 2026, 11:38 pm
Pharmaids Pharma: VP of Discovery Services Resigns Dr. Jagadeesh M N has resigned from his position as Vice President – Discovery Services and Senior Management Personnel at Pharmaids Pharmaceuticals. The resignation, tendered for personal reasons, is effective from the close of business hours on 25 Jun'26. The company disclosed this leadership change to the stock exchange as per Regulation 30 of SEBI Listing Regulations. This departure represents a key change in the leadership of the company's crucial Discovery Services division.
Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Providing corporate guarantee to subsidiary, Adita Bio Sys Private Limited
Others (Uncategorized) · 13 Jun 2026, 3:40 pm
Pharmaids Pharmaceuticals Provides Corporate Guarantee to Material Subsidiary Pharmaids Pharmaceuticals issued a corporate guarantee on 13th Jun'26 for its unlisted material subsidiary, Adita Bio Sys Private Limited. The guarantee secures a new loan facility availed by Adita under the ECLGS 5.0 scheme. An agreement for Rs. 55 lakhs was executed with the State Bank of India, against a board-approved limit of Rs. 75 lakhs. Promoters have no interest in the transaction. The guarantee represents a contingent liability for Pharmaids with no immediate financial impact on the listed entity.
Submission of Audited Financial Results along with Auditors Report.
Financial Result · 30 May 2026, 1:01 am
Pharmaids Board Approves FY26 Results & Corporate Guarantee for Subsidiary On 29-May'26, Pharmaids Pharmaceuticals' board approved audited FY26 results and a corporate guarantee up to ₹75 lakhs for its subsidiary, Adita Bio Sys Private Limited. For FY26 (consolidated), revenue from operations grew to ₹2,788.24 lakhs from ₹1,944.74 lakhs YoY. However, Net Loss widened to ₹1,157.19 lakhs from ₹1,350.51 lakhs in FY25. The Q4FY26 consolidated net loss was ₹108.49 lakhs, improving from a loss of ₹480.31 lakhs YoY. The audit report from PPKG & Co was unmodified.
The Board of Directors of the Company have approved the Audited Financial Results for the quarter and year ended March 31, 2026 at their meeting held on May 29, 2026.
Outcome · 30 May 2026, 12:50 am
Pharmaids Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lacs) ■ Revenue: 718 (+50.7% YoY | +32.3% QoQ) ■ EBITDA: -33.9 (+91.3% YoY | +86.5% QoQ) ■ EBITDA Margin (%): -4.7 (+7725 bps YoY | +4140 bps QoQ) ■ PAT: -181 (+54.1% YoY | +27.0% QoQ) ■ EPS (INR): -0.51 (+54.1% YoY | +27.1% QoQ)
Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Intimation · 29 May 2026, 5:30 am
Pharmaids Pharma Board Meeting on May 29 to Approve Q4 and FY26 Results Pharmaids Pharmaceuticals (BSE: 524572) has scheduled a Board of Directors meeting on 29 May'26 to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended 31 Mar'26. The trading window for designated persons is closed and will reopen 48 hours after the results are declared to the stock exchange, in accordance with SEBI insider trading regulations.
Sale of entire shareholding held by Adita Bio Sys Private Limited (material subsidiary of the Company) in Siri Labvivo Diet Private Limited, a step-down subsidiary, resulting in cessation ....
Others (Uncategorized) · 28 Mar 2026, 3:11 am
Pharmaids Pharmaceuticals Disposes of Step-Down Subsidiary for Rs. 3 Lakhs Pharmaids Pharmaceuticals announced the sale of its step-down subsidiary, Siri Labvivo Diet Private, via its material subsidiary Adita Bio Sys. The transaction was completed on 27th Mar'26 for a consideration of Rs. 3,00,000. As of 31st Mar'25, the divested unit contributed 0.73% (Rs. 14.11 lakh) to consolidated revenue and had a negative net worth contribution of (1.62)% or Rs. (89.11 lakh). The buyer, Mr. Shivakumar B G, is not part of the promoter group. Siri Labvivo has ceased to be a subsidiary.
Intimation under Regulation 30 of LODR.
Others (Uncategorized) · 25 Feb 2026, 3:01 am
Pharmaids Subsidiary Adita Bio Sys Receives Key US Accreditation Pharmaids Pharmaceuticals' material subsidiary, Adita Bio Sys, received accreditation from the American Association for Laboratory Accreditation (A2LA) on 24 Feb '26. The approval covers testing of medical devices in the biological field per ISO/IEC 17025:2017 standards. The accreditation also meets specific program requirements under U.S. FDA Good Laboratory Practice (GLP) regulations, per 21 CFR Part 58, enhancing its competence and compliance for international markets. This development is a key operational milestone for the subsidiary.
Report of Auditors on Financial Results for the quarter and nine months ended December 31, 2025 with UDIN
Others (Uncategorized) · 13 Feb 2026, 3:52 am
Pharmaids Pharma Submits Auditors' Review Report for Q3 and 9M FY26 Pharmaids Pharmaceuticals submitted its standalone and consolidated auditors' review reports for the quarter and nine months ended 31 Dec'25. The reports, issued on 12 Feb'26, provide a conclusion on the unaudited financial results. Auditors noted they did not review the financials of two subsidiaries, which reported total revenues of ₹459.71 lakhs and a net loss of ₹46.38 lakhs for the quarter. The auditors' conclusion on the consolidated statement was based on reports from other auditors for these entities and is not modified.
Unaudited financial results for the quarter and nine months ended December 31, 2025
Financial Result · 13 Feb 2026, 1:24 am
Pharmaids Pharmaceuticals Q3 FY26 Results Show Widening Losses on Lower Revenue Pharmaids Pharmaceuticals reported a widening standalone net loss of ₹310.98 Lacs for Q3 FY26, compared to a loss of ₹159.29 Lacs in Q3 FY25. Revenue from operations declined 31.1% YoY to ₹83.28 Lacs. On a consolidated basis, the net loss for the quarter was ₹264.60 Lacs versus a loss of ₹301.45 Lacs YoY. Consolidated revenue grew 15.3% YoY to ₹543.00 Lacs. The company announced the discontinuation of a lease agreement with Koye Lifesciences effective 01 Dec'25.
Outcome of the Board Meeting held on Thursday, February 12, 2026, i.e, today, to consider and approve the un-audited financial results for the quarter and nine months ended December 31, 2025.
Outcome · 13 Feb 2026, 1:18 am
Pharmaids Pharmaceuticals Limited - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lacs) ■ Revenue: 543 (+15.3% YoY | -36.9% QoQ) ■ EBITDA: -250 (+13.2% YoY | +53.0% QoQ) ■ EBITDA Margin (%): -46.1 (+1514 bps YoY | +1574 bps QoQ) ■ PAT: -248 (-28.2% YoY | +1.4% QoQ) ■ EPS (INR): -0.70 (-27.3% YoY | +1.4% QoQ)
Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 12 Feb 2026, 5:30 am
Pharmaids Pharma Board Meeting on 12 Feb'26 for Q3FY26 Results Pharmaids Pharmaceuticals has scheduled a Board of Directors meeting on 12 Feb'26 to consider and approve its Unaudited Financial Results (Standalone & Consolidated). The results will cover the quarter and nine months ending 31 Dec'25. In line with SEBI regulations, the trading window for designated persons remains closed and will reopen 48 hours after the results are declared. This meeting is a key event for assessing the company's Q3FY26 performance.
Report on shares re-lodged for transfer cum Demat of Physical shares.
Others (Uncategorized) · 16 Jan 2026, 9:23 pm
Pharmaids Reports No Physical Share Transfer Requests in Special Window Pharmaids Pharmaceuticals informed BSE on 16 Jan '26 about the status of re-lodgement requests for physical share transfers. The report from its Registrar and Transfer Agent, dated 07 Jan '26, confirms that as of 06 Jan '26, no requests were received, processed, approved, or rejected under the special window provided by the SEBI circular dated 02 Jul '25. This indicates zero activity related to the physical-to-demat transfer process during the specified period.
Intimation regarding completion of term of Independent Director of Mr. Mopperthy Sudheer
Change in Management · 05 Jan 2026, 11:33 pm
Pharmaids Pharmaceuticals Announces Independent Director's Term Completion Pharmaids Pharmaceuticals (BSE: 524572) announced that Mr. Mopperthy Sudheer has completed his term as an Independent Director, effective from the close of business hours on 05 Jan'26. Consequently, he has also ceased to be a member of the Audit Committee and the Nomination & Remuneration Committee. The departure is due to the natural completion of his directorship tenure. This change in board and committee composition is a key governance update for the company.
Outcome of the circular resolution dated January 05, 2026 for the reconstitution of the Audit and Nomination and Remuneration Committee of the Board.
Others (Uncategorized) · 05 Jan 2026, 10:43 pm
Pharmaids Pharmaceuticals Announces Board Committee Reconstitution Pharmaids Pharmaceuticals reconstituted its Audit and Nomination & Remuneration Committees, effective from Jan 06, 2026. For the Audit Committee, Mr. Pattamadai Natarajasarma Vijay was appointed Chairman. The committee now comprises three Independent Directors and one Whole-time Director. Mr. Methuku Nagesh will chair the Nomination & Remuneration Committee, which is now composed entirely of Independent Directors. The changes were approved via a circular resolution on Jan 05, 2026, enhancing corporate governance structures.
This is to inform you that shareholders of the company have approved the appointment of Dr. Yogananda Moolemath (DIN: 02870387) as an Independent Director of the Company.
Change in Management · 02 Jan 2026, 8:43 pm
Pharmaids Pharmaceuticals Appoints Dr. Yogananda Moolemath as Independent Director Pharmaids Pharmaceuticals has appointed Dr. Yogananda Moolemath as an Independent Director for a five-year term, effective 01 Jan '26. The appointment was approved by shareholders via postal ballot, with results declared on 02 Jan '26. Dr. Moolemath is a toxicologist with over 30 years of experience in drug discovery, development, and regulatory science. He is currently the Chief Scientific Officer & Co-Founder of Vittarthaa Life Sciences and has held senior roles at various pharmaceutical and CRO organizations. He has no relations with other board members.
Report on re-lodgment of requests for transfer of Physical shares
Others (Uncategorized) · 12 Dec 2025, 8:55 pm
Pharmaids Reports No Physical Share Transfer Requests as of Dec'25 Pharmaids Pharmaceuticals filed an update on the re-lodgement of transfer requests for physical shares, pursuant to a SEBI circular. As of 05 Dec'25, the company's Registrar and Transfer Agent confirmed it received NIL requests during the month. Consequently, no requests were processed, approved, or rejected under the special window provided. This indicates no recent shareholder activity related to converting or transferring physical share certificates for the reported period.